Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1997-08-08
1999-09-28
Spivack, Phyllis G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514274, 514812, A61K 3170, A61K 31505
Patent
active
059588969
ABSTRACT:
Disclosed herein is a method for reducing stimulant dependencies in mammals that involves administration of a therapeutically-effective amount of a cytosine-containing or cytidine-containing compound, such as CDP-choline.
REFERENCES:
Teoh, S.K. et al., J. Clin. Psychopharmacology, 1993; 13: 87-99, Acute Interactions of Buprenorphine with Intravenous Cocaine and Morphine: An Investigational New Drug Phase I Safety Evaluation.
Maas, L.C. et al., Am J Psychiatry, 1998; 155(1):124-126, Functional Magnetic Resonance Imaging of Human Brain Activation During Cue-Induced Cocaine Craving.
English, C.D., et al., Biol Psychiatry, 1997; 41:500-502, Elevated Frontal Lobe Cytosolic Chloine Levels in Minimal or Mild AIDS Dementia Complex Patients: A Proton Magnetic Resonance Spectroscopy Study.
Sholar, M.B., et al., Journal of Clinical Endocrinology and Metabolism, 1998; 83(3):966-968, Concurrent Pharmacokinetic Analysis of Plasma Cocaine and Adrenocorticotropic Hormone in Men.
Kaufman, M. J., et al., JAMA, 1998; 279(5):376-380, Cocaine-Induced Cerebral Vasoconstriction Detected in Humans with Magnetic Resonance Angiography.
Brown et al., "CNS Complications of Cocaine Abuse: Prevalence, Pathophysiology, and Neuroradiology," AJR Am. J. Roentgenol., 159:137-147 (1992).
Chang et al., "Neurochemical Alternations in Asymptomatic Abstinent Cocaine Users: A Proton Magnetic Resonance Spectroscopy Study," Biol. Psychiatry, 42:1105-1114 (1997).
Hoff et al., "Effects of Crack Cocaine on Neurocognitive Function," Psychiatry Res., 60:167-176 (1996).
Jacobs et al., "Cocaine Abuse: Neurovascular Complications," Radiology, 170:223-227 (1989).
Kreek, "Opiate and Cocaine Addictions: Challenge for Pharmacotherapies," Pharmacol. Biochem. Behav., 57:551-569 (1997).
McCance, "Overview of Potential Treatment Medications for Cocaine Dependence," NIDA Res. Monogr., 175:36-72 (1997).
Peterson et al., "Neurovascular Complications of Cocaine Abuse," J. Neuropsychiatry Clin. Neurosci., 3:143-149 (1991).
Warner et al., "Pharmacotherapy for Opioid and Cocaine Abuse," Med. Clin. North Am., 81:909-925 (1997).
Saligaut, C. et al., Neuropharmacology, 1987; 26(9):1315-1319, Circling Behaviour in Rats with Unilateral Lesions of the Nigrostriatum Induced by 6-Hydroxydopamine: Changes Induced by Oral Administration of Cytidine-5'-Diphosphocholine.
O'Rourke, M.M. et al., Life Sciences, 1996; 59(2), 119-130, Effect of Chronic Cocaine Exposure on Carotid Artery Reactivity in Neonatal Rabbits.
Christensen, J.D. et al., Magnetic Resonance in Medicine, 1996; vol. 35:658-663, Abnormal Cerebral Metabolism in Polydrug Abusers During Early Withdrawal: A .sup.31 P MR Spectroscopy Study.
London, E.D. et al., Res. Comm. Subst. Abuse, 1989; 10:141-144, Cerebral Glucose Utilization in Human Heroin Addicts: Case Reports from a Positron Emission Tomographic Study.
Levin, J.M. et al., J. Nucl. Med., 1995; 36:1211-1215, Improved Regional Cerebral Blood Flow in Chronic Cocaine Users Treated with Buprenorphine.
Agnoli, A. et al., Novel Biochemical, Pharmacological and Clinical Aspects of Cytidinediphosphocholine, New York, NY: Elsevier Science Publishing Co., Inc., 1985; 30:305-315, Efficacy of CDPcholine in Chronic Cerebral Vascular Diseases (CCVD).
Boudouresques, B.A. et al., International Symposium: Brain Suffering and Precursors of Phospholipids: Paris, Jan. 18, 1980, Therapeutic Conduct in Light of a Cerebral Vascular Accident and the Use of CDP-Choline.
Centrone, G. et al., Minerva Med., 1986; 77:371-373, Use of Citicoline in High Dosages in Acute Cerebrovascular Disease.
Moglia, A. et al., Curr Ther Res., 1984; 36:309-313, Citicoline in Patients with Chronic Cerebrovascular Diseases (CCVD): Quantitative EEG Study.
Salvadorini, F. et al., Curr Ther Res., 1975; 18:513-520, Clinical Evaluation of CDP-Choline (Nicholin.RTM.): Efficacy as Antidepressant Treatment.
Tazaki, Y. et al., Stroke, 1988; 19:211-216, Treatment of Acute Cerebral Infarction with a Choline Precursor in a Multicenter Double-Blind Placebo-Controlled Study.
Babb, S.M. et al., Psychopharmacology 1996; 127:88-94, Differential Effect of CDP-Choline on Brain Cytosolic Choline Levels in Younger and Older Subjects as Measured by Proton Magnetic Resonance Spectroscopy.
Gallai, V. et al., Psychopharmacology 1991; 103:1-5, Study of the P300 and Cerebral Maps in Subjects with Multi-Infarct Dementia Treated with Cytidine.
Galletti, P. et al., J Neurol. Sci., 1991; 103:S19-S25, Biochemical Rationale for the Use of CDP-Choline in Traumatic Brain Injury: Pharmacokinetics of the Orally Administered Drug.
Weiss, G.B., Life Sci., 1995; 56:637-660: Metabolism and Actions of CDP-Choline as an Endogenous Compound and Administered Exogenously as Citicoline.
Cohen, Bruce M. et al., JAMA, 1995; vol. 274, No. 11, 902-907, Decreased Brain Choline Uptake in Older Adults, An In Vivo Proton Magnetic Resonance Spectroscopy Study.
Secades, J.J. et al., Methods Find. Exp. Clin. Pharmacol. 1995 ; 17 (Suppl B):1-54, CDP-Choline: Pharmacological and Clinical Review.
Self, David W. et al., Science, 1996; 271:1586-1589, Opposite Modulation of Cocaine-Seeking Behavior by D.sub.1 -and D.sub.2 -Like Dopamine Receptor Agonists.
Citicoline Sodium (CDP-Choline), Investigator's Brochure, Revised: Apr. 1994 by Interneuron Pharmaceuticals, Inc.
Lukas Scott
Renshaw Perry F.
Spivack Phyllis G.
The McLean Hospital
LandOfFree
Cytidine-containing and cytosine-containing compounds as treatme does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cytidine-containing and cytosine-containing compounds as treatme, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cytidine-containing and cytosine-containing compounds as treatme will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-703288